ESR2, estrogen receptor 2, 2100

N. diseases: 73; N. variants: 19
Disease: Prostatic Neoplasms ×
Source: CURATED ×
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Therapeutic group CTD_human The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues. 26443449 2015
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Biomarker group CTD_human The mRNA levels of PPFIBP2 and ESR2 are differentially expressed in prostate tumours and paired normal tissues. 26443449 2015
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Biomarker group CTD_human Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma. 17639508 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Therapeutic group CTD_human Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma. 17639508 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Biomarker group CTD_human Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. 16921512 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Therapeutic group CTD_human Apigenin suppresses cancer cell growth through ERbeta. 17132221 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Biomarker group CTD_human Apigenin suppresses cancer cell growth through ERbeta. 17132221 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Therapeutic group CTD_human Dietary intake of phytoestrogens, estrogen receptor-beta polymorphisms and the risk of prostate cancer. 16921512 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Therapeutic group CTD_human [Implications of estrogens and their receptors for the development and progression of prostate cancer]. 16220300 2005
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Biomarker group CTD_human [Implications of estrogens and their receptors for the development and progression of prostate cancer]. 16220300 2005
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Therapeutic group CTD_human The evolving role of estrogen therapy in prostate cancer. 15046698 2002
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.400 Biomarker group CTD_human The evolving role of estrogen therapy in prostate cancer. 15046698 2002